Chemomab Therapeutics Ltd.
CMMBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CMMB. That does not mean none is planned.
Get an email about CMMB's next catalysts
Track Chemomab Therapeutics (CMMB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
How CMMB's past catalysts played out
Market Overview
Stock performance and key metrics
Anti-human CCL24 monoclonal antibody (CM-101)
Primary Sclerosing Cholangitis
CM-101
Nonalcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Anti-human CCL24 monoclonal antibody (CM-101) | Phase 2 | Primary Sclerosing Cholangitis | - | - |
CM-101 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Frequently asked questions
What is in Chemomab Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Chemomab Therapeutics Ltd.'s (CMMB) pipeline across Phase 2. Its lead program is Anti-human CCL24 monoclonal antibody (CM-101) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Chemomab Therapeutics Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Chemomab Therapeutics Ltd. (CMMB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CMMB biotech catalysts?→
Add CMMB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Chemomab Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.